[HTML][HTML] Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular …
A Jiménez-Ubieto, A Martín-Muñoz, M Poza… - Frontiers in …, 2023 - frontiersin.org
Background CART therapy has produced a paradigm shift in the treatment of relapsing FL
patients. Strategies to optimize disease surveillance after these therapies are increasingly …
patients. Strategies to optimize disease surveillance after these therapies are increasingly …
[HTML][HTML] Interobserver variability in interim PET assessment in Hodgkin lymphoma—reasons and solutions
TW Georgi, L Kurch, D Hasenclever, VS Warbey… - PLoS …, 2023 - journals.plos.org
Introduction Interim PET (iPET) assessment is important for response adaptation in Hodgkin
lymphoma (HL). The current standard for iPET assessment is the Deauville score (DS). The …
lymphoma (HL). The current standard for iPET assessment is the Deauville score (DS). The …
[HTML][HTML] Analysis of Positive Results of 18F-FDG PET/CT Imaging after Hematopoietic Stem Cell Transplantation in Lymphoma
N Dai, R Cai, S Deng, S Sang - Diagnostics, 2023 - mdpi.com
Purpose: The purpose of this study was to differentiate between false-positive and true-
positive positron emission tomography (PET) results after hematopoietic stem cell …
positive positron emission tomography (PET) results after hematopoietic stem cell …